
Choksi Laboratories Ltd. (CHOKSILA) 52 Week High Streak: Consecutive High Analysis
Updated: 15 Oct 2026 • 9:39 am
Posted by:

Choksi Laboratories Ltd. 52 Week High Streak has extended to a second straight session, with the stock staying close to its one-year peak across the streak. According to latest Univest data, the cumulative change across the two-session stretch is 3.18%, which keeps the move on market radars even though the latest intraday trade was lower than the previous close.
The stock opened at Rs 220, touched a high of Rs 226.65 and a low of Rs 209. That range shows how the session moved around the upper end of the recent band, while the repeated proximity to the peak keeps the Choksi Laboratories Ltd. 52 Week High Streak in focus rather than a one-off fluctuation.
Choksi Laboratories Ltd. (CHOKSILA) 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 214.4 |
| Previous Close | Rs 216.65 |
| Today's Move | Rs -2.25 (-1.04%) |
| Open | Rs 220 |
| High | Rs 226.65 |
| Low | Rs 209 |
| Market Capitalisation | Rs 150.9 crore |
Choksi Laboratories Ltd. (CHOKSILA) traded at Rs 214.4 versus the previous close of Rs 216.65, a fall of 1.04%. The stock opened at Rs 220, reached a high of Rs 226.65 and touched a low of Rs 209.
What the Repeated 52-Week Highs Show
The Choksi Laboratories Ltd. 52 Week High Streak is best read as a pattern of sustained proximity to the annual high. When a stock keeps trading near its top range for more than one session, it signals that the market is still willing to price it near recent highs instead of quickly backing away. That is the key distinction in this update.
In this case, the latest Univest figures confirm a second straight session within 2% of the 52-week high. The first session near the peak serves only as the factual anchor for the streak; the focus now is the repeated behaviour. For readers tracking the Choksi Laboratories Ltd. 52 Week High Streak, the important point is continuity: the stock remained close to its yearly high even while the latest trade sat below the day’s best level.
Choksi Laboratories Ltd. (CHOKSILA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 150.9 crore |
| P/E Ratio | 69.83x |
| P/B Ratio | 5.77x |
| ROE | 6.65% |
| ROCE | 9.45% |
| EPS | Rs 3.1 |
| Book Value Per Share | Rs 37.56 |
| Dividend Yield | 0% |
Choksi Laboratories Ltd. (CHOKSILA) fundamental metrics show P/E 69.83x, P/B 5.77x, ROE 6.65%, ROCE 9.45%. These figures provide context only and are not a buy or sell signal.
Choksi Laboratories Ltd. has a market capitalisation of Rs 150.9 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 69.83x, P/B at 5.77x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 6.65% and ROCE of 9.45%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 3.1, book value per share of Rs 37.56, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 13.42x, median ROE of 10.43%, median ROCE of 13.3%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Business Services |
| Industry | Business Support |
| Benchmark Scope | same industry |
| Company P/E Ratio | 69.83x |
| Benchmark Median P/E | 13.42x |
| Benchmark Average P/E | 37.5x |
| Benchmark P/E Range | 0x to 368.39x |
| Company P/B Ratio | 5.77x |
| Benchmark Median P/B | 1.63x |
| Company ROE | 6.65% |
| Benchmark Median ROE | 10.43% |
| Company ROCE | 9.45% |
| Benchmark Median ROCE | 13.3% |
| Company Market Capitalisation | Rs 150.9 crore |
| Benchmark Median Market Cap | Rs 170.31 crore |
Choksi Laboratories Ltd. (CHOKSILA) is classified under sector: Business Services and industry: Business Support.
Choksi Laboratories Ltd. (CHOKSILA) has a P/E ratio of 69.83x, which is above the benchmark median of 13.42x, a difference of +420.34%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Choksi Laboratories Ltd. (CHOKSILA) has a ROE of 6.65%, which is below the benchmark median of 10.43%, a difference of -36.24%. Choksi Laboratories Ltd. (CHOKSILA) has a ROCE of 9.45%, which is below the benchmark median of 13.3%, a difference of -28.95%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Justo Realfintech Limited | JUSTO | 150.39 | 7.73 | 1.18 | 21.49 | 27.17 |
| G V ELECTRICALS LTD | GVELECTRIC | 138.85 | 13.27 | 1.91 | 0 | 0 |
| Mitcon Consultancy & Engineering Services Ltd. | MITCON | 135.85 | 13.78 | 0.84 | 6.32 | 9.36 |
| Infollion Research Services Ltd. | INFOLLION | 170.31 | 13.42 | 2.55 | 21.04 | 28.64 |
| Crown Lifters Ltd. | CROWN | 131.12 | 14.54 | 1.63 | 41.43 | 33.1 |
Choksi Laboratories Ltd. (CHOKSILA) has a P/E ratio of 69.83x compared with the displayed peer median of 13.42x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 6.65% compares with a peer median of 21.04% across the companies shown in the table. ROCE stood at 9.45% versus the displayed peer median of 27.17%, providing a capital-efficiency comparison. Choksi Laboratories Ltd. (CHOKSILA) has a market capitalisation of Rs 150.9 crore. Among the 5 peers shown, 1 has a larger market capitalisation.
Why Investors Are Watching Choksi Laboratories Ltd.
- It has traded within 2% of its 52-week high for a second straight session.
- The cumulative change across the streak is 3.18%.
- Market cap stands at Rs 150.9 crore, based on latest Univest figures.
- P/E at 69.83x is well above the same-industry median.
- ROE and ROCE remain below the benchmark medians.
About Choksi Laboratories Ltd.
Choksi Laboratories Ltd. operates in the Business Services sector and the Business Support industry. The company sits in a small market-cap bracket at Rs 150.9 crore, based on latest Univest figures. Its valuation and return ratios show a business that the market prices at a premium relative to peers, even while profitability metrics remain modest. That combination makes the Choksi Laboratories Ltd. 52 Week High Streak more interesting from a market-reading angle, because price behaviour and fundamentals are not moving in perfect lockstep.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
What was the latest price of Choksi Laboratories Ltd.?
Ans. The stock stood at Rs 214.4 according to latest Univest data. It traded below the previous close of Rs 216.65, but the broader point is that it remained close to the annual high range.
How far was Choksi Laboratories Ltd. from its 52-week high?
Ans. The stock was trading within 2% of its 52-week high. That proximity is the key feature behind the Choksi Laboratories Ltd. 52 Week High Streak and the reason the move is being tracked.
What is the market capitalisation of Choksi Laboratories Ltd.?
Ans. Market capitalisation stood at Rs 150.9 crore, according to latest Univest figures. That gives readers a size reference before looking at valuation ratios, return ratios and the repeated near-high price behaviour.
How do the valuation ratios look for Choksi Laboratories Ltd.?
Ans. The company’s P/E ratio is 69.83x and its P/B ratio is 5.77x. In the latest Univest figures, both sit above the same-industry medians, which suggests a clear valuation premium.
How do the return ratios compare with peers?
Ans. ROE is 6.65% and ROCE is 9.45%. Those levels are below the same-industry medians in the latest Univest figures, which helps explain why the stock’s market pricing stands out.
Why is the sector context important in this update?
Ans. Choksi Laboratories Ltd. operates in Business Services and Business Support, where peers show a wide range of valuation and return profiles. That context helps place the Choksi Laboratories Ltd. 52 Week High Streak inside its industry backdrop.
Does the repeated near-high trading confirm a forecast for the stock?
Ans. No. The repeated near-high trading only describes the observed pattern. It does not establish a target, forecast or recommendation, and the latest Univest figures are used here strictly for market context.
Track Choksi Laboratories Ltd. (CHOKSILA) Share Price on Univest
Use Choksi Laboratories Ltd. (CHOKSILA) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Recent Articles

Stocks to Buy for 2027: Ventura's Samvat 2083 Picks Include HDFC Bank, Paytm, Meesho, Ather, LG Electronics India and Park Medi World, With Targets Up to 75% Above the Price at Publication
13 November 2026

Microsoft Outage on 13 November 2026 Sends Traders Back to Phones and Fax: What the Outlook, Teams and Copilot Failure Means for Global Markets, Indian Brokerages and Investors
13 November 2026

Ingersoll Rand Dividend of Rs 20 Per Share: Record Date 19 November 2026, Payout on 2 December and What the Q2 FY27 Profit Rise of 9% Says About the Payout and the Stock
13 November 2026

Viceroy Hotels Share Price Gains Nearly 4% After Q2 FY27 Results: Revenue Up 56.5% to Rs 48.20 Crore but Profit Halves to Rs 2.23 Crore, and Why the Rs 106 Crore Rights Issue Matters on 13 November 2026
13 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Stocks to Buy for 2027: Ventura's Samvat 2083 Picks Include HDFC Bank, Paytm, Meesho, Ather, LG Electronics India and Park Medi World, With Targets Up to 75% Above the Price at Publication
Microsoft Outage on 13 November 2026 Sends Traders Back to Phones and Fax: What the Outlook, Teams and Copilot Failure Means for Global Markets, Indian Brokerages and Investors
Ingersoll Rand Dividend of Rs 20 Per Share: Record Date 19 November 2026, Payout on 2 December and What the Q2 FY27 Profit Rise of 9% Says About the Payout and the Stock
Viceroy Hotels Share Price Gains Nearly 4% After Q2 FY27 Results: Revenue Up 56.5% to Rs 48.20 Crore but Profit Halves to Rs 2.23 Crore, and Why the Rs 106 Crore Rights Issue Matters on 13 November 2026
SC Agrotech Bonus Issue and Stock Split: 4:5 Bonus and 1:10 Split Proposed as the Stock Locks a 5% Upper Circuit at Rs 62.38, Q2 Profit Up 48 Times and What Shareholders Should Check Before the 11 December EGM

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





